O. Fiche, Hormonothérapie par inhibiteur de l'aromatase : Arimidex (Anastrozole, Fémara (Létrozole) et Aromasine (Exémestane)

M. Aapro, R. Audisio, A. Hurria, D. Schrijervs, H. Van-halteren et al., European Society for Medical Oncology. Handbook of cancer in the senior patient

K. Agrawal, S. Onami, and J. Mortimer, Cognitive changes associated with endocrine therapy for breast cancer, Maturitas, vol.67, issue.3, pp.209-214
DOI : 10.1016/j.maturitas.2010.07.004

URL : http://europepmc.org/articles/pmc3253817?pdf=render

J. Aiache, J. Besner, and P. Leblanc, Traité de biopharmacie et de pharmacocinétique, 3 ème édition, p.384, 1997.

M. Aitichou, V. Colloud, and C. Terret, Pharmacie clinique en oncog??riatrie??: d??marche et ??valuation au sein de consultations interdisciplinaires, Le pharmacien hospitalier et clinicien, pp.127-128, 2014.
DOI : 10.1016/j.phclin.2014.04.263

V. Antoine, B. De-wazières, and N. Houédé, Attentes des professionnels hospitaliers impliqu??s dans la prise en charge globale en oncog??riatrie, Bulletin du Cancer, vol.102, issue.2, pp.150-161, 2015.
DOI : 10.1016/j.bulcan.2014.12.011

L. Balducci and M. Extermann, Management of Cancer in the Older Person: A Practical Approach, The Oncologist, vol.5, issue.3
DOI : 10.1634/theoncologist.5-3-224

G. Barbeau, J. Guimond, and L. Mallet, Médicaments et personnes âgées ; édition Maloine, 1991.

G. Barbeau, L. Grenier, J. Guimond, and L. Mallet, Manuel des soins pharmaceutiques en gériatrie, pp.624-126, 2003.

J. Bergerat, Place actuelle des??inhibiteurs de??l'aromatase dans??le??traitement adjuvant des??cancers du??sein, Presse Medicale, pp.333-373, 2007.
DOI : 10.1016/j.lpm.2006.12.019

C. Berthozat, R. Boulieu, and J. Charbonnel, Guide d'aide à l'usage des anticancéreux disponibles en officine, p.392

L. Biganzoli, H. Wildiers, and C. Oakman, Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA), The Lancet Oncology, vol.13, issue.4, pp.148-60, 2012.
DOI : 10.1016/S1470-2045(11)70383-7

V. Bleret, J. Collignon, and P. Coucke, L'observance au traitement de longue durée : le cas particulier de l'hormonothérapie adjuvante du cancer du sein, Rev Med Liège, vol.65, pp.405-408, 2010.

J. Body, P. Bergmann, and S. Boonen, Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club, Osteoporosis International, vol.176, issue.6 Pt 2
DOI : 10.7326/0003-4819-144-10-200605160-00009

K. Broekhuizen, A. Pothrof, A. De-craen, and S. Mooijaart, Characteristics of Randomized Controll Trials Designed for Elderly: A systematic Review, PLoS ONE, vol.2015, issue.105, p.8

A. Brufsky, N. Bundred, and R. Coleman, Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole, The Oncologist, vol.13, issue.5, pp.503-514, 2008.
DOI : 10.1634/theoncologist.2007-0206

A. Buzdar, J. Robertson, and W. Eiermann, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane, Cancer, vol.43, issue.9, pp.2006-2016, 2002.
DOI : 10.1016/0960-0760(92)90198-R

M. Cecile, O. Dalco, and V. Pauly, Accidents iatrog??nes m??dicamenteux chez le sujet ??g?? hospitalis?? en court s??jour g??riatrique??: ??tude de pr??valence et des facteurs de risques, La Revue de M??decine Interne, vol.30, issue.5, pp.393-400, 2009.
DOI : 10.1016/j.revmed.2009.01.010

W. Cheung, E. Lai, and J. Ruan, Comparative adherence to oral hormonal agents in older women with breast cancer, Breast Cancer Research and Treatment, vol.2013, issue.4, pp.419-427, 2015.
DOI : 10.1200/EdBook_AM.2013.33.265

A. Coates, A. Keshaviah, and B. Thrülimann, Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98, Journal of Clinical Oncology, vol.25, issue.5, pp.5-486, 2007.
DOI : 10.1200/JCO.2006.08.8617

G. Colloca, A. Corsonello, and E. Marzetti, Treating Cancer in Older and Oldest Old Patients, Current Pharmaceutical Design, vol.21, issue.13, pp.1699-1705, 2015.
DOI : 10.2174/1381612821666150130122536

R. Coombes, L. Kilburn, and C. Snowdon, Survival and safety of exémestane versus tamoxifène after 2-3 years' tamoxifène treatment (Intergroup Exemestane Study): a randomized controlled trial, The Lancet, vol.369, pp.9561-559, 2007.

B. Cutuli, A. Lesur, and E. Luporsi, Place des inhibiteurs de l'aromatase dans le cancer du sein de la femme ménopausée, en situation adjuvante : les acquis et les incertitudes en, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, vol.35, pp.327-340, 2005.

M. Daroux, C. Gaxatte, and F. Puisieux, Vieillissement rénal : facteurs de risque et néphroprotection. La presse médicale, pp.1667-1679, 2009.
DOI : 10.1016/j.lpm.2008.12.027

F. Debiais, Inhibiteurs de l'aromatase, analogues de la LH-RH et ostéoporose. Revue du rhumatisme monographies 78, pp.81-87, 2011.
DOI : 10.1016/j.monrhu.2011.02.003

S. Diab, R. Elledge, and G. Clark, Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancer, Journal of the National Cancer Institute, vol.92, issue.7, pp.550-556, 2000.
DOI : 10.1093/jnci/92.7.550

I. Doutriaux-dumoulin and P. Meingan, Surveillance des cancers du sein??: doit-on adapter le suivi selon l?????ge??? La femme ??g??e, Imagerie de la Femme, vol.23, issue.2, pp.87-91, 2013.
DOI : 10.1016/j.femme.2013.03.005

E. Dufay, La conciliation des traitements médicamenteux : qualité et sécurité des soins liées aux produits de santé : la parcours de soins, 2013.

E. Louis-marie, Modalités diagnostiques du cancer du sein chez la femme, à partir de 75 ans, en Gironde : rôle du médecin généraliste. Human health and pathology, pp.2013-01001030

M. Extermann, G. Albrand, and H. Chen, Are Older French Patients As Willing As Older American Patients to Undertake Chemotherapy?, Journal of Clinical Oncology, vol.21, issue.17, p.17, 2003.
DOI : 10.1200/JCO.2003.08.091

I. Fatfouta, Tolérance des inhibiteurs de l'aromatase : étude transversale chez 106 patientes en Lorraine, Thèse pour l'obtention du grade de Docteur en Médecine, 2010.

C. L. Frodeau, hormonothérapie dans le cancer du sein et l'observance des traitements

S. Garnier, La pharmacie clinique en pratique : création d'un outil de formation destiné aux internes et étudiants en pharmacie, p.94, 2007.

J. Gaymu, Aspects démographiques du vieillissement. Institut national d'études démographiques, Paris ; BEH n°5-6, 2006.

P. Goss, J. Ingle, and S. Martino, A randomized trial of Letrozole in postmenopausal women after five years of Tamoxifen therapy for early-stage breast cancer, The New England Journal of Medicine, vol.349, pp.19-1793, 2003.

P. Hadji, J. Body, and M. Aapro, Practical guidance for the management of aromatase inhibitor-associated bone loss, Annals of Oncology, vol.100, issue.20, pp.1407-1416, 2008.
DOI : 10.1001/jama.298.20.2389

M. Héry, J. Gligorov, and M. Namer, Cancer du sein, 2007.

A. Howell, J. Cuzick, and M. Baum, of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer, The Lancet, vol.365, pp.9453-60, 2005.

A. Hurria, S. Gupta, and M. Zauderer, Developing a cancer-specific geriatric assessment, Cancer, vol.20, issue.9
DOI : 10.1038/bjc.1991.305

URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.21422/pdf

M. Laroche, F. Bouthier, L. Merle, and J. Charmes, M??dicaments potentiellement inappropri??s aux personnes ??g??es??: int??r??t d???une liste adapt??e ?? la pratique m??dicale fran??aise, La revue de médecine interne, pp.592-601, 2009.
DOI : 10.1016/j.revmed.2008.08.010

L. Jeunne, C. , and D. D. Dorosz, Guide pratique des médicaments. Maloine 31 ème édition, 2012.

S. Lichtman and . Polypharmacy, Polypharmacy: Geriatric Oncology Evaluation Should Become Mainstream, Journal of Clinical Oncology, vol.33, issue.13
DOI : 10.1200/JCO.2014.60.3548

URL : http://hwmaint.jco.ascopubs.org/cgi/reprint/33/13/1422.pdf

S. Lichtman, L. Balducci, and M. Aapro, Geriatric Oncology: A Field Coming of Age, Journal of Clinical Oncology, vol.25, issue.14, pp.1821-1823, 2007.
DOI : 10.1200/JCO.2007.10.6567

R. Maggiore, C. Gross, and A. Hurria, Polypharmacy in older adults with cancer. The Oncologist, pp.507-522, 2010.

R. Maggiore, C. Gross, and K. Togawa, Use of complementary medications among older adults with cancer, Cancer, vol.88, issue.15S, pp.4815-4823, 2012.
DOI : 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I

R. Maggiore, W. Dale, and C. Gross, Polypharmacy and Potentially Inappropriate Medication Use in Older Adults with Cancer Undergoing Chemotherapy: Effect on Chemotherapy-Related Toxicity and Hospitalization During Treatment, Journal of the American Geriatrics Society, vol.5, issue.15S, pp.1505-1512, 2014.
DOI : 10.1016/j.amjopharm.2007.12.002

A. Mclean, L. Couteur, and D. , Aging Biology and Geriatric Clinical Pharmacology, Pharmacological Reviews, vol.56, issue.2, pp.163-184, 2004.
DOI : 10.1124/pr.56.2.4

. Ministère-du-travail,-de-l-'emploi-et-de-la-santé, Arrêté du 4 mai 2012 portant approbation de la convention nationale organisant les rapports entre les pharmaciens titulaires d'officine et l'assurance maladie, Journal officiel de la République Française, pp.51-131, 2012.

F. Molinié and . Sein, Survie des personnes atteintes de cancer en France 1989-2007 ? Etude à partir des registres des cancers du réseau Francim, INVS, 2013.

J. Morère and M. Rainfray, Cancer du sujet âgé deuxième édition. Collection oncologie pratique, 2007.

D. Morisky, L. Green, and D. Levine, Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence, Medical Care, vol.24, issue.1, pp.67-74, 1986.
DOI : 10.1097/00005650-198601000-00007

J. Mortimer and J. Urban, Long term toxicities of Selective Estrogen-Receptor Modulators and Antiaromatase Agents, Cancer Network, p.8, 2003.

S. Mueller, C. Sponsler, K. Kripalani, and S. , Hospital-Based Medication Reconciliation Practices, Archives of Internal Medicine, vol.172, issue.14, pp.2012-1057
DOI : 10.1001/archinternmed.2012.2246

URL : http://archinte.jamanetwork.com/data/journals/intemed/24628/iiq120035_1057_1069.pdf

G. Nightingale, E. Hajjar, and K. Swartz, Evaluation of a Pharmacist-Led Medication Assessment Used to Identify Prevalence of and Associations With Polypharmacy and Potentially Inappropriate Medication Use Among Ambulatory Senior Adults With Cancer, Journal of Clinical Oncology, vol.33, issue.13
DOI : 10.1200/JCO.2014.58.7550

P. Pageau, Développement de l'oncogériatrie : prise en charge officinale d'une personne âgée atteinte d'un cancer du sein traitée par la Capécitabine (Xeloda) Thèse pour le diplôme d, 2009.

. Prescrire, Eviter les effets indésirables par interactions médicamenteuses comprendre et décider, 2012.

G. Prithviraj, S. Koroukian, and S. Margevicius, Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer, Journal of Geriatric Oncology, vol.3, issue.3, pp.228-237, 2012.
DOI : 10.1016/j.jgo.2012.02.005

D. Reid, J. Doughty, and R. Eastell, Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group, Cancer Treatment Reviews, vol.34
DOI : 10.1016/j.ctrv.2008.03.007

L. Rey, Médicaments potentiellement inappropriés chez la personne âgée : analyse de prévalence à partir des prescriptions médicales de ville. Pharmaceutical sciences, 2012.

J. Rey, D. Parent, and F. Scotté, Rôle du pharmacien hospitalier en soins oncologiques de support, J Pharm Clin, vol.34, issue.1, pp.7-10, 2015.

V. Paul-de, cancer du sein » et soins de support » Parties I et II, pp.10-11, 2009.

K. Ruddy, E. Mayer, and A. Partridge, Patient adherence and persistence with oral anticancer treatment, CA: A Cancer Journal for Clinicians, vol.59, issue.1, pp.56-66, 2009.
DOI : 10.3322/caac.20004

URL : http://onlinelibrary.wiley.com/doi/10.3322/caac.20004/pdf

F. Salvi, M. Miller, and A. Towers, Manuel de directives pour la cotation de l'échelle « Modified cumulative illness rating scale (CIRS), 2013.
DOI : 10.1111/j.1532-5415.2008.01935.x

S. Servitja, T. Martos, R. Sanz, and M. , Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance, Therapeutic Advances in Medical Oncology, vol.85, issue.5, pp.2015-291
DOI : 10.1056/NEJMoa052258

M. Schonberg, E. Marcantonio, and D. Li, Breast Cancer Among the Oldest Old: Tumor Characteristics, Treatment Choices, and Survival, Journal of Clinical Oncology, vol.28, issue.12, pp.12-2038, 2010.
DOI : 10.1200/JCO.2009.25.9796

URL : http://europepmc.org/articles/pmc2860406?pdf=render

P. Soubeyran, Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.29, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.9001

P. Soubeyran, C. Bellera, and J. Goyard, Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study, PLoS ONE, vol.49, issue.12, p.133
DOI : 10.1371/journal.pone.0115060.s002

M. Vandendriessche, Patients âgés : une campagne pour développer le « réflexe iatrogénie, p.20, 2015.

C. Van-poznak, R. Hannon, and J. Mackey, Prevention of Aromatase Inhibitor???Induced Bone Loss Using Risedronate: The SABRE Trial, Journal of Clinical Oncology, vol.28, issue.6, pp.6-967, 2010.
DOI : 10.1200/JCO.2009.24.5902

S. Yahiaoui and . Cancer-du-sein, Synthèse et évaluation de dérivés flavonoïdiques inhibiteurs de l'aromatase. Thèse pour obtenir le grade de Docteur de l, p.171, 2005.

R. Yancik and P. Carbone, National Cancer Institute, et al. Perspectives on Prevention and Treatment of Cancer in the Elderly, pp.1-342, 1983.

X. Wang, J. Bonventre, and A. Parrish, The Aging Kidney: Increased Susceptibility to Nephrotoxicity, International Journal of Molecular Sciences, vol.27, issue.12, pp.15358-15376, 2014.
DOI : 10.1159/000329385